trending Market Intelligence /marketintelligence/en/news-insights/trending/NNMjCN9T1i3IMaRQaAjXHQ2 content esgSubNav
In This List

ESMO conference: Incyte's drug reduces tumors in bile duct cancer patients

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


ESMO conference: Incyte's drug reduces tumors in bile duct cancer patients

Incyte Corp.'s experimental drug pemigatinib during a mid-stage study reduced the size of tumors in patients with a rare bile duct cancer.

In a phase 2 trial called Fight-202, the Wilmington, Del.-based biotech is evaluating the safety and efficacy of pemigatinib in adult patients with cholangiocarcinoma whose cancer has spread to nearby tissues or to another site in the body.

Cholangiocarcinoma is a rare type of cancer that develops in the bile ducts, which connect the liver to the gallbladder and small intestine. It is often diagnosed at a late stage, the company noted in its Sept. 27 press release. The disease currently has no standard of care beyond initial chemotherapy.

Incyte said 36% of patients with a certain gene mutation who took pemigatinib showed a reduction in tumor size, the main goal of the study. Three of the patients had no detectable cancer after treatment and 35 participants partially responded to the treatment. Patients in the study lived for an average of 6.9 months without their disease worsening or dying.

The findings were presented at the European Society for Medical Oncology 2019 Congress on Sept. 27. Incyte expects to submit a marketing approval application for pemigatinib with the U.S. Food and Drug Administration before the end of 2019.

Pemigatinib, a type of treatment known as a fibroblast growth factor receptor, or FGFR1/2/3, inhibitor, is also being tested as a treatment for bladder cancer.

The European Society for Medical Oncology is holding its 2019 scientific meeting in Barcelona, where more than 3,900 study abstracts have been submitted for review by oncology professionals from around the world.